GFPC 06-2018: A Multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Atezolizumab;Pemetrexed;Bevacizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: GFPC 06-2018: A Multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies ### Output: Atezolizumab;Pemetrexed;Bevacizumab